LONDON, February 7, 2012 /PRNewswire/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special

LONDON, July 26, 2011 /PRNewswire/ -- UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum. In an interview with financial broadcaster http://www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining "headwinds", R&D strategy, improving margins and a review of the recently implemented Drug Performance Units. The interview and transcript are available now on http://www.cantos.com/company/glaxosmithkline. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives.

PHILADELPHIA, Oct.

LONDON, February 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007. In an interview on http://www.cantos.com CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of R&D. He said: "Now obviously I don't like to see anybody leave the organisation or there to be any job losses.

PHILADELPHIA, Feb. 1 /PRNewswire-FirstCall/ -- On Thursday, February 4, 2010, GlaxoSmithKline plc will announce its full year financial results for the year ended December 31, 2009.